Venous thromboembolism prevention with low molecular weight heparin may reduce hemorrhagic transformation in acute ischemic stroke

[1]  M. Zoli,et al.  Predicting hemorrhagic transformation and its timing from maximum cerebral lesion diameter in nonlacunar ischemic strokes , 2019, Brain and behavior.

[2]  R. Sacco,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. , 2019, Stroke.

[3]  Pengfei Guo,et al.  A meta-analysis of randomized controlled trials , 2019, Medicine.

[4]  Keith W. Muir,et al.  Do Clinicians Overestimate the Severity of Intracerebral Hemorrhage? , 2019, Stroke.

[5]  M. Zoli,et al.  Predicting cerebral edema in ischemic stroke patients , 2019, Neurological Sciences.

[6]  Kwang-Soo Lee,et al.  Blood-brain barrier permeability assessed by perfusion computed tomography predicts hemorrhagic transformation in acute reperfusion therapy , 2018, Neurological Sciences.

[7]  J. Simard,et al.  Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease , 2017, Molecules.

[8]  Pavlović M. Aleksandra,et al.  European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke , 2017 .

[9]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[10]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[13]  Yilong Wang,et al.  Frequency and risk factors of spontaneous hemorrhagic transformation following ischemic stroke on the initial brain CT or MRI: data from the China National Stroke Registry (CNSR) , 2016, Neurological research.

[14]  P. Sandercock,et al.  European Stroke Organisation (ESO) guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke , 2016, European stroke journal.

[15]  A. Hillis,et al.  Predicting Hemorrhagic Transformation of Acute Ischemic Stroke , 2016, Medicine.

[16]  W. Ageno,et al.  Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing The RAF Study , 2015, Stroke.

[17]  B. Nilsson,et al.  Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation , 2015, Thrombosis and Haemostasis.

[18]  M. Huang,et al.  Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. , 2015, Cytokine.

[19]  S. Realmuto,et al.  Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[20]  M. Brainin,et al.  European Stroke Organisation , 2013 .

[21]  Yi Liu,et al.  Hemorrhagic transformation in acute ischemic stroke , 2013 .

[22]  P. Sandercock,et al.  Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials , 2013, The Lancet Neurology.

[23]  Xin Sun,et al.  Neuroprotective Effects of Ultra-Low-Molecular-Weight Heparin on Cerebral Ischemia/Reperfusion Injury in Rats: Involvement of Apoptosis, Inflammatory Reaction and Energy Metabolism , 2013, International journal of molecular sciences.

[24]  D. Leys,et al.  Asymptomatic Hemorrhagic Transformation of Infarction and Its Relationship With Functional Outcome and Stroke Subtype: Assessment From the Tinzaparin in Acute Ischaemic Stroke Trial , 2010, Stroke.

[25]  W. Ageno,et al.  Acute Hyperglycemia and Early Hemorrhagic Transformation in Ischemic Stroke , 2009, Cerebrovascular Diseases.

[26]  H. Winn,et al.  Regulation of cerebral vasculature in normal and ischemic brain , 2008, Neuropharmacology.

[27]  Giancarlo Comi,et al.  Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome: Results of a Prospective Multicenter Study , 2008, Stroke.

[28]  J. Mocco,et al.  O‐DESULFATED HEPARIN IMPROVES OUTCOME AFTER RAT CEREBRAL ISCHEMIA/REPERFUSION INJURY , 2007, Neurosurgery.

[29]  D. Rossi,et al.  Astrocyte metabolism and signaling during brain ischemia , 2007, Nature Neuroscience.

[30]  J. Babb,et al.  Measuring Elevated Microvascular Permeability and Predicting Hemorrhagic Transformation in Acute Ischemic Stroke Using First-Pass Dynamic Perfusion CT Imaging , 2007, American Journal of Neuroradiology.

[31]  K. Wong,et al.  Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study , 2007, The Lancet Neurology.

[32]  Giancarlo Agnelli,et al.  Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials , 2007, Stroke.

[33]  M. Nugent,et al.  New insights into the inhibition of human neutrophil elastase by heparin. , 2006, Biochemistry.

[34]  P. Sandercock,et al.  Frequency and risk factors for spontaneous hemorrhagic transformation of cerebral infarction. , 2004, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[35]  J. Weinberger.  Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. , 2003, Current cardiology reports.

[36]  P. Deyn,et al.  Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial , 2001, The Lancet.

[37]  H. Nader,et al.  Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates. , 2000, Biochimica et biophysica acta.

[38]  P. Bath,et al.  Low-molecular-weight heparins and heparinoids in acute ischemic stroke : a meta-analysis of randomized controlled trials. , 2000, Stroke.

[39]  J. Marler,et al.  Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. , 1999, Stroke.

[40]  L Bozzao,et al.  Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. , 1999, Stroke.

[41]  A. Shuaib,et al.  Posttreatment with low molecular weight heparin reduces brain edema and infarct volume in rats subjected to thrombotic middle cerebral artery occlusion , 1998, Brain Research.

[42]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[43]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[44]  G. Sette,et al.  Hemorrhagic transformation of brain infarct , 1996, Neurology.

[45]  A. Ahuja,et al.  Low-molecular-weight heparin for the treatment of acute ischemic stroke , 1995 .

[46]  R. Linhardt,et al.  Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. , 1993, Blood.

[47]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[48]  S. Marklund,et al.  The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity. , 1992, The Journal of biological chemistry.

[49]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[50]  J. Rankin.  Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis , 1957, Scottish medical journal.